ICU, ICUCW · CIK 0001831868 · operating
SeaStar Medical develops a selective cytopheretic device (SCD) platform designed to treat hyperinflammatory conditions affecting critical organs. The device functions as a disease-modifying therapy by neutralizing over-active immune cells and interrupting cytokine storms that drive destructive inflammation. The company's proprietary technology targets the underlying immunological mechanisms rather than symptoms alone.
The company's primary clinical program is QUELIMMUNE, an SCD-based therapy for pediatric patients with acute kidney injury due to sepsis, which has advanced to commercial stage. NEUTRALIZE-AKI, a variant formulation for adult patients with acute kidney injury, remains in clinical development. SeaStar is also exploring applications across additional therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease patients.
SeaStar Medical operates as a compact organization with 19 full-time employees and is headquartered in Denver, Colorado. The company is listed on Nasdaq and was incorporated in Colorado. As a commercial-stage medical device company, it generates revenue primarily through its clinical and commercial activities in the United States market.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-6.63 | $-6.63 | -447.9% | |
| 2023 | $-1.21 | $-1.21 | +56.8% | |
| 2022 | $-2.80 | $-2.80 | — | |
| 2021 | — | — | — |